When your investment case breaks down, why not just do the decent thing?
ApexOnco Front Page
Recent articles
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
The move follows promising but early data presented at ASCO.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Roche dumps another partnered asset.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
